1. Metabolic Enzyme/Protease
  2. Proteasome

MG-101 (Synonyms: Calpain inhibitor I; ALL)

Cat. No.: HY-18964 Purity: >95.0%
Data Sheet SDS Handling Instructions

MG-101 is a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM).

For research use only. We do not sell to patients.
MG-101 Chemical Structure

MG-101 Chemical Structure

CAS No. : 110044-82-1

Size Price Stock Quantity
10 mM * 1 mL in DMSO $86 In-stock
5 mg $78 In-stock
10 mg $120 In-stock
50 mg $400 In-stock
100 mg $650 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References


MG-101 is a potent inhibitor of cysteine proteases including calpain I (Ki = 190 nM), calpain II (Ki = 220 nM), cathepsin B (Ki = 150 nM), and cathepsin L (Ki = 500 pM). IC50 value: 150 nM (Ki) Target: cysteine protease in vitro: MG-101 is a calpain inhibitor (IC50 = 0.09 μM) that activates p53-dependent apoptosis in tumor cell lines. At 10-100 μM MG-101 dose-dependently prevents the degradation of IκBα and IκBβ by the ubiquitin-proteasome complex, which blocks activation of NFκB and the production of TNF and IL-1β, suggesting a potential therapeutic effect for inflammatory diseases.2 At 10 μM, MG-101 can inhibit nitric oxide production by activated macrophages by interfering with transcription of the inducible nitric oxide synthase gene. In HCT116 cells, MG-101 decreases cell viability and tumor growth, and induces apoptosis response through Bax translocation from cytosol to mitochondria. [1] in vivo: In mice bearing HCT116 xenografts, MG-101 (10 mg/kg i.p.) inhibits colon tumor formation. [1]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT02289755 Allena Pharmaceuticals Hyperoxaluria|Nephrolithiasis September 2014 Phase 2
NCT02547805 Allena Pharmaceuticals Secondary Hyperoxaluria|Nephrolithiasis|Hyperoxaluria|Kidney Stones|Dietary Hyperoxaluria September 2015 Phase 2
NCT02503345 Allena Pharmaceuticals Secondary Hyperoxaluria|Nephrolithiasis|Kidney Stones|Hyperoxaluria|Dietary Hyperoxaluria July 2015 Phase 2
NCT03095885 Allena Pharmaceuticals Secondary Hyperoxaluria|Nephrolithiasis|Hyperoxaluria|Kidney Stones November 2016
View MoreCollapse
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.6074 mL 13.0368 mL 26.0736 mL
5 mM 0.5215 mL 2.6074 mL 5.2147 mL
10 mM 0.2607 mL 1.3037 mL 2.6074 mL






Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name



Applicant name *


Email address *

Phone number


Organization name *

Country *


Requested quantity *


Bulk Inquiry

Inquiry Information

Product Name:
Cat. No.: